Melanoma Institute Australia shines at prestigious Cancer Research Awards
3 November 2018
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has won the top award for Outstanding Cancer Researcher of the Year. One of the world’s pre-eminent melanoma clinicians and researchers, Professor Long has changed the face of melanoma treatment around the world with her ground-breaking clinical trials tripling life expectancy for patients with advanced melanoma and curing a significant subset.
Fellow MIA Co-Medical Director, Professor Richard Scolyer, has been awarded The Professor Rob Sutherland AO Make a Difference Award, which is awarded in recognition of lasting impact and sustained progress to cancer care or research practice. Professor Scolyer is the world’s leading melanoma pathologist, each year receiving more than 2,000 cases for review and opinion from around the world. He recently co-edited the new WHO Classification of Skin Tumours, 4th Edition.
Also awarded were MIA’s Associate Professor Alex Menzies, who won the Outstanding Cancer Research Fellow Award with less than five years post-doctoral experience in research, and Associate Professor Anne Cust, who was awarded Outstanding Cancer Research Fellow with more than five years post-doctoral experience in research.
Associate Professor Menzies is a Medical Oncologist with research interest in clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Associate Professor Cust is an epidemiologist whose research focuses on melanoma epidemiology, prevention, early detection and survivorship and has a strong emphasis on translational outcomes.
Melanoma Institute Australia CEO Matthew Browne said it was a proud moment to see Melanoma Institute Australia’s research and clinical team centre stage at the prestigious awards night.
‘This is well deserved recognition for not only these award winners, but also the multi-disciplinary teams across MIA that work tirelessly to develop new treatments to save lives from melanoma,’ Mr Browne said.
‘My particular congratulations go to Professor Long for taking out the prestigious Outstanding Cancer Researcher of the Year Award. This is testament to her research and global thought leadership which has set the world on the path towards advanced melanoma becoming a chronic disease rather than a terminal one.
‘She was gracious in acknowledging the award was recognition of the whole team’s efforts at MIA, and particularly her long research partnership with Professor Richard Scolyer.
‘With the breakthroughs in melanoma treatment also set to revolutionise treatments for other cancers, Professor Long’s legacy will potentially impact millions across the globe.’
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Melanoma March physical events in 2022
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Melanoma Bike Bash 2021: What a ride!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
MIA researchers awarded $7.2m in NHMRC grants for health research
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Honouring Ben's life by supporting the next generation of melanoma researchers
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
MIA's annual Research Retreat 2021
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Understanding the needs of Stage III melanoma patients when choosing treatments.
Independent researchers at The University of Sydney are seeking patient feedback.
Community Fundraising Wrap Up Apr-June 2021
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Patients paying it forward
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
Research boost to improve outcomes for melanoma patients
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Amie St Clair 10th Annual Ball
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina Melanoma Ride
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Melanoma Clinical Trial to open in Wagga
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
Queen's Birthday Honour for Professor Richard Scolyer
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
Sharing our research on the global stage at 2021 ASCO Annual Meeting
Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21.
Australian researchers lead world in successful trial of new cancer treatment.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Thank you doesn't seem enough for our melanoma nurses.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.